The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
Ketanserin, a selective S2-receptor antagonist was evaluated in a double-blind parallel placebo-controlled trial of 29 patients with Raynaud's phenomenon. The effect on finger blood flow was assessed by strain-gauge plethysmography during a standardised cooling stress. Ten normal healthy controls also had finger blood flow assessments made in the same way. The Ketanserin group showed a significantly greater improvement (P less than 0.05) in finger blood flow at minimum flow temperature than the placebo group. The results suggest that the local release of serotonin may play a role in Raynaud's phenomenon and that Ketanserin can modify the abnormal response in finger blood flow.
Dormandy
J A
JA
Department of Vascular Surgery, St James' Hospital, London, U.K.
Berent
A
A
Downes
S J
SJ
D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005385:Fingers / Q000098:blood supply; D006801:Humans; D007650:Ketanserin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology
D007650:Ketanserin